
Join us at the next N=1 Collaborative seminar led by Marlen Lauffer to discuss recommendations for evaluation of disease causing variants. Register: bit.ly/3Lq6J3I

Working together to bring individualized genetic medicines safely and rapidly to patients worldwide

Join us at the next N=1 Collaborative seminar led by Marlen Lauffer to discuss recommendations for evaluation of disease causing variants. Register: bit.ly/3Lq6J3I

Individualized medicine provides new opportunities for targeted therapies for rare disease patients, but not all individuals affected by rare disease are eligible for tailored N=1 approaches.

Our N=1 Collaborative seminars are open to everyone and we encourage questions and discussion!

Join us for a case study on Monday, September 11, at 12:30 pm US EDT to hear about ASO treatment for SCN2A-encephalopathy, allele-specific vs non-specific, with Heather Olson and Elizabeth Berry-Kravis. Register here: bit.ly/487WDhC

The event is open to all, please join us: bit.ly/3KSMpYs

@UrnovFyodor and Manar Zaghlula from the Innovative Genomics Institute will join the @N1Collaborative Seminar Series on Monday 8/28 at 12:30-1:30p EST to share a framework and recommendations for enabling affordable, accessible bespoke CRISPR treatments.

For N-of-1/few treatments in rare genetic disease, while antisense oligos may be the initial therapeutic platform of choice, CRISPR holds huge promise for the future.

Our N=1 Collaborative seminars are open to everyone and we encourage questions and discussion! Join Live: bit.ly/3rBemxh

Join us for a case study on Monday, July 31, at 12:30 pm US EDT to hear about a novel antisense oligonucleotide for CMT2S, a rare subtype of Charcot-Marie-Tooth Disease, with Sandra Smieszek of Vanda Pharmaceuticals.

Join us live on July 17, 2023 at 12:30 pm US ET: bit.ly/3DcKwSb

Join Andrew Lo, @MIT Sloan Professor of Finance, this Monday for a dynamic seminar hosted by the @N1Collaborative. We will discuss the portfolio model in rare disease therapeutics, the role of philanthropy, and reimbursement considerations in the individualized medicine context.

Joining this discussion will be a panel of innovators from Integrated DNA Technologies, Cytiva, and La Jolla Labs Inc. Join Live: bit.ly/46wLhTT

What if coding personalized ASO therapies only required the press of a button? Join us Monday, July 10, at 12:30pm US EDT, and Vanessa Almendro of @DanaherCorp to discuss the paradigm shift needed to make therapeutic interventions for rare genetic diseases accessible to patients.

The talk will include novel approaches like the Multi-Domain Responder Index, as well as how to incorporate biomarkers. Join Live: bit.ly/3ITqcJ3 @stopbatten @winstonxyan @timyu

Join Emil Kakkis, CEO of Ultragenyx & Richard Finkel, MD, Director, Center for Experimental Neurotherapeutics, St. Jude Children's Hospital, at the @N1Collaborative seminar Monday, June 5 at 12:30 PM EDT to discuss how to think about outcome measures for individualized medicines.

Join us on Monday, May 22, at 12:30pm US EDT, for the next @N1Collaborative seminar to discuss this critical topic with Dr. Matthis Synofzik and Dr. Rebecca Schüle from University of Tuebingen Join live: https://t.co/Pmidn3hR9M